Vertex announces positive results from phase 2 study of vx-548 for the treatment of painful diabetic peripheral neuropathy

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced positive results from its phase 2 dose-ranging study of the selective nav1.8 inhibitor vx-548 in people with painful diabetic peripheral neuropathy (dpn). treatment with all doses of vx-548 resulted in a statistically significant and clinically meaningful reduction in the primary endpoint of change from baseline in the weekly average of daily pain intensity on a numeric pain rating scale (nprs) at week 1.
VRTX Ratings Summary
VRTX Quant Ranking